Abdulrahman Abdulbaki, MD
Interventional Cardiology · Des Moines, IANPI 1972701050
Payments from drug & device makers
Across 591 payments — averaging $72.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$29K
- Medtronic$5K
- Boston Scientific$2K
- Abbott$2K
- Edwards Lifesciences$1K
- Inari Medical, Inc.$1K
- plus $3K from 22 others
What the payments were for
- Speaking & faculty fees$26,25061%
- Travel & lodging$5,20412%
- Food & beverage$11,56327%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 169 | $28,921 |
| Medtronic(2 entities) | 56 | $5,123 |
| Boston Scientific | 103 | $1,900 |
| Abbott | 99 | $1,737 |
| Edwards Lifesciences | 10 | $1,247 |
| Inari Medical, Inc. | 52 | $1,085 |
| Cardiovascular Systems Inc. | 13 | $954 |
| AstraZeneca | 6 | $354 |
| Novartis | 22 | $327 |
| Shockwave Medical, Inc | 6 | $261 |
| Abiomed | 18 | $260 |
| Stryker | 4 | $191 |
| Penumbra, Inc. | 2 | $158 |
| Pfizer | 7 | $107 |
| Astellas Pharma US Inc | 1 | $100 |
| Chiesi USA, Inc. | 4 | $76 |
| Johnson & Johnson | 4 | $51 |
| Angiodynamics, Inc. | 2 | $45 |
| Bayer | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Boehringer Ingelheim | 2 | $31 |
| Novo Nordisk | 1 | $22 |
| Lantheus Medical Imaging, Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $18 |
| Biotronik Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Amgen | 1 | $15 |
| Teleflex LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$26,512
- ADVISA DR MRI SURESCAN$2,415
- SYMPLICITY G3$994
- Edwards SAPIEN 3 Transcatheter Heart Valve$925
- FLOWTRIEVER CATHETER, S$874
- Diamondback Coronary$734
- CT THROMBECTOMY SYSTEM KIT$612
- WATCHMAN Access System$342
- COREVALVE EVOLUT R$315
- FARXIGA$290
- LINQ II$169
- ADVISOR$160
- Indigo System$152
- AMPLATZER AMULET$150
- CoreValve Evolut$143
- WATCHMAN FLX$125
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$114
How this compares
$43,117 in reported general payments places this provider in the 80th percentile of 64 interventional cardiology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 273 | $247,752 |
| JardianceEmpagliflozin | 123 | $111,212 |
| EntrestoSacubitril/Valsartan | 86 | $79,298 |
| FarxigaDapagliflozin Propanediol | 67 | $57,122 |
| XareltoRivaroxaban | 66 | $53,724 |
| Repatha SureclickEvolocumab | 18 | $21,187 |
| Atorvastatin Calcium | 528 | $3,097 |
| Ranolazine ErRanolazine | 24 | $2,935 |
| Metoprolol Succinate | 280 | $2,595 |
| Bumetanide | 63 | $2,318 |
| ClopidogrelClopidogrel Bisulfate | 241 | $2,110 |
| Ezetimibe | 54 | $1,613 |
| Losartan Potassium | 124 | $968 |
| Lisinopril | 193 | $944 |
| Amlodipine Besylate | 185 | $888 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $107 | $247,752273 claims |
| Boehringer IngelheimJardiance | $31 | $111,212123 claims |
| NovartisEntresto | $327 | $79,29886 claims |
| AstraZenecaFarxiga | $354 | $57,12267 claims |
| Johnson & JohnsonXarelto | $51 | $53,72466 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 64 interventional cardiology providers in Iowa.
Other interventional cardiology in Des Moines
- Atul ChawlaDes Moines$485K
- David McAllisterDes Moines$149K
- Daniel ShivapourDes Moines$135K
- Musab AlqasrawiDes Moines$6K
- Ravinder DerveshDes Moines$3K
- Hamza OglatDes Moines$924
- Aaron FromDes Moines$793
- Martin AronowDes Moines$232
- Nicolas ShammasDavenport$4.8M
- Phillip HorwitzIowa City$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.